Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
설정
언어
한국어
통화
USD
테마
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
주식 순위 #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
주가
$0.04443294
마지막 동기화: 2026-09-24
시가총액
$13.65M
변동 (1일)
0.00%
변동 (1년)
-35.28%
국가
AU
거래 Noxopharm Limited (NOX)

카테고리

Healthcare
Noxopharm Limited (NOX)의 발행 주식 수
June 2026 기준 발행 주식 수: 290.49M
Noxopharm Limited의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 290.49M입니다. June 2024 말 기준 회사는 292.26M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Noxopharm Limited (NOX)의 발행 주식 수 기록 (2016 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 290.49M -0.67%
2025 292.47M 0.07%
2024 292.26M 0.01%
2023 292.24M 0.35%
2022 291.22M 10.37%
2021 263.85M 90.70%
2020 138.36M 0.15%
2019 138.15M 16.06%
2018 119.03M 35.93%
2017 87.57M 160.94%
2016 33.56M 0.00%
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -12.60%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 36.32%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 64.86%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -78.59%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH